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I. Project Investigator: Heath H. Herman, Ph. D. 
Project Title: Bioassay of Novel Antihypertensive Agents 
Period of Support: July 1, 1981 to June 30, 1982 
II. Project Report 
The research cork supported by the American Heart Association Georgia 
hate in the above-mentioned project has been quite productive. This project 
as its purpose the initial enzymatic investigation and the initial bioassay of 
Dnergic activity of a number of novel adrenergic neurotransmitter analogS which 
considered to have potential as new antinypertensive proto-drugs. In - the work 
rormed under the auspices of this grant we have used a continuous 02 monitor 
*' developed in this laboratory (phillips, et al.(1980) Fed. Proc. 2, 2936) to 
form the enzymatic assays for dopamine-beta-hydroxylase (DBH) activity and for mo 
>amine oxidase (MAO). We have used three different types of bioassay methods in 
testing of our prototype compounds. These were: (1) rabbit ileal segment con- 
. 
tion assays of adrenergic receptor agonism and antagonism; (2) anesthetized dog 
•d pressure and heart rate monitoring with intravenous infusion of prototype 
pounds; and (3) spontaneously hypertensive rat (SHR) tail-cuff systOlic blood 
sure monitoring with subcutaneous application of prototype compounds. 
By way of background, we have designed and synthesized prototypic compounds of 
De distinct classes which were the subjects of investigation in this project. 
ye classes of compounds were: (1) Ketone-generating analogs; (2) Olefinic analogs 
(3) Sulfur-containing analogs. Our results with each of these classes will be - 
::ussed separately (see original proposal for more detail). 
)ne-Generating Analog 
In the original proposal, we mentioned our discovery of the oxygenation of s-
zylic alcohols by DBH. This work was published (JBC 256, 2258, 1981) and a 
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int is attached to this report. Two extensions of this enzymatic ketonization 
were also published during the grant period_ and are also attached (JBC 256,8470, 
and BBRC 121, 38, 1981). We have recently found that S-octopamine is a poor 
trate for MAO, with a K m at least one power of ten greater than comparable sub-
tee, although this work is still preliminary. In in vitro and in vivo experi- 
ation using the methods outlined. earlier, we nave found that: (1) S-octopamine 
esses very little alpha- or beta-adrenergic agonistic activity; (2) this comp- 
possesses very little adrenergic antagonistic activity in vitro (at least 10 2 
than propranolol) And similarly, in vivo, appears to exert very little adrener-
antaonistic activity;.and (3) at large doses (ca. 1 mg/kg) s-octopamine causes 
redirect sympathomimetic effect in anesthetized dogs when given intravenously. 
inic Analogs  
In our original proposal we suggested working with two olefinic prototypic 
'minds. One of these, 1-phenyl-(1-aminomethyl)ethene (PANE), has proved to be a 
' exciting find. To recapitulate, we theorized that an unsaturated functionality 
ted at the benzylic position in a molecule designed to resemble a DBH substrate 
d !fool" the enzyme into attempting to oxygenate this double bond with the re-
:Lng formation of a highly reactive epoxide (see original proposal for structure 
details). This prediction has now been almost completely realized. PANE is an 
:Llent substrate for oxygenation by DBH and the 1:2 oxygen to electron stoichio-
y we have determined is diagnostic of oxygenation by the normal monooxygenase 
way. We have determined a Km of 8.3 mM and a k cat of 10/sec for PANE using the 
en monitor kinectics assay . method. Most importantly, we have conclusively 
nstrated time-dependant inactivation of DBH by PAME and have shown that this in-
vation is irreversible to dialysis and is ascorbate dependent. Additionally, we 
now identified the ultimate product of DBH oxygenation of PANE as the 1-phenyl- 
lnomethyl-glycol which we contend is derived from the initial epoxide by hydrol- 
4 In similar oxygen-uptake experiments, we have demonstrated that PAM is antex- 
ent MAO substrate, with a Km of 1.2 mM and a kcat of 0.5/sec. In in vitro and 
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Ln vivo experiments, we have found that PAME is not a direct adrenergic agonist 
Lther alpha or beta receptors and is a very weak adrenergic antagonist. It is 
rer, a potent indirect sympathomimetic with characteristics similar to those of 
topamine discussed previously. The work with PAME discussed above is currently 
g organized into a large paper which will be submitted this fall to the Journal  
iological Chemistry.. Because PAME will be the first demonstration of the oxi-
Dn of an olefin by DBH, and because of its potential significance for medical 
arch (discussed here in the conclusions), we believe that this paper will be 
e significant. 
ur-Containing Analogs 
Our final class of novel neurotransmitter analogs has proved to be the most int-
ting of all, and the work reported below holds the most promise for an eventual 
lopement into an actual clinical tool. To recapitulate, we had earlier found 
DBH catalyzed the oxygenation of benzylic sulfidei when the sulfur atom was in-
orated into a phenylethylamine-like molecule of our own design (JACS 102, 5981, 
). Subsequent work led to the developement of a series of Para-substituted sul-
analogs whose kinetic characteristics in DBH-catalyzed oxygenations led to new 
ence for the enzymatic mechanism (see attached reprint, JBC 256, WO, 1981). 
ork carried out under the auspices of this grant, we have found that our proto- 
sulfur compound, phenyl-2-aminoethylsulfide (PAES), is quite an excellent MAO 
trate, with a Km of 0.08 mM and a kcat of 0.63/sec. Thus, PAES is the best sub- 
to for MAO of all of our prototypic compounds, a fact of some significance, as 
be discussed below. In it vitro and in vivo adrenergic receptor assays, PAES 
our other analogs, proved to have very little alpha- or beta-adrenergic agonist 
vity. Similarly, PAES exerts a very small adrenergic antagonism at the receptor 
1. Again, as was the case for our other two classes of compounds, PAES proved t 
't significant indirect sympathomimetic activity in intravenous infusions into 
ithetized dogs at large doses (ca. 1 mg/kg). In a detailed series of dose res-, . 
:e experiments with PAES infusion into anesthetized dogs however, a number of 
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dug findings were observed. First, the supposition that PAES was exerting an 
rect sympathomimetic effect was confirmed in a number of experiments in which its 
cts were completely bloCked by cocaine pretreatment. Secondly, we have demon-
ted that reserpine pretreatment (3 mg/kg, 24 hours) also completely blocks the 
rect sympathomimetic effects of PAES. Thus, PAES is somehow interfering with a 
anism involving the catecholamine reuptake system and vesicular storage of neuro-
smitter in adrenergic neurons. These findings led us to a series of in vivo 
riments using anesthetized dogs in which the ability of the sympathetic reflex 
rol of blood pressure was examined after pretreatment with a fixed dose of PAES. 
results of these experiments were quite remarkable. In one series of experiments 
med hydralazine, a known vasodilator, to elicit a sympathetic reflexive increase 
keart rate. After pretreatment with 4 mg/kg PAES, this reflexive tachycardia 
to hydralazine was abolished, suggesting that sympathetic nerve pathways were 
de to respond to the hypotension caused by hydralazine. Similarly, the beta 2 
)onse in arterial smooth muscle to norepinephrine ( a relaxation leading to de-
tses in blood pressure) were much prolonged after pretreatment with the same dose 
'AES, again suggesting a diminuition of sympathetic reflex activity. These re- 
,s have been incorporated into a manuscript presently under review for publication 
;he Journal of Cardiovascular Pharmacology and a copy of this manuscript is 
mded herein. 
Finally, we have obtained evidence for a direct antihypertensive effect for PAES 
xamining its effects on sHR. Using age-matched SHR males we have examined the 
tots of chronic administration of 5, 10, 25, and 50 mg/kg subcutaneous injections 
'AES, measuring the systolic blood pressure of the conscious animal using an in- 
ct tail-cuff plethysmographic method. The animals remained conscious at all 
during the experimentation, betrayed no behavioral changes as a result of the 
treatment, and sustained no weight losses as a result of the treatment. We have 
id that the drug is non-toxic in this model up to the highest levels tested so far 
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that its blood pressure-lowering effects are reversible after withdrawal of the 
g. In our most striking experiment to date, groups of SHR and saline-treated SHR 
trols received either 50 mg/kg PAES or saline (1 mg/kg) s.q. at 24 hour intervals 
seven consecutive days. Blood pressure monitoring revealed a 15-20 % reduction 
the PAES-treated group, apparent at-24 hours, and maintained for seven days. 
:se results suggest that the antihypertensive potential of these compounds is well 
!th continued investigation. 
Iclusions-- Lay summa 
Our success in the synthesis, enzymatic testing, and biassay of these three new 
asses of adrenergic analogs is a result of an exciting and highly productive calla-
ration between biochemists at Ga. Tech and pharmacologists at Mercer University 
athern School of Pharmacy. We cannot emphasize too strongly the the importance of 
✓ findings with respect to the biological activity of our sulfur -containing analog, 
ES. Its direct antihypertensive activity and its ability to act synergistically 
th a currently-used vasodilatory antihypertensive, hydralazine, to remove the 
fleiive cardioacceleratory side-effects suggest that PAES has a high potential for 
e eventual developement into an important clinical tool. The parallel indication's 
indirect sympathomimesis with test compounds from the other two classes suggest 
at they too might exhibit similar effects upon closer examination. Additionally, 
✓ findings with respect to our olefinic analogs suggest that they could be used to 
lectively down-regulate sympathetic activity by inactivating dopamine beta-hydroxy-
se molecules and thus lowering norepinephrine synthesis. 
III. Collaborators 
Dr. Stanley H. Pollock, Assoc. proffessor of Biomedical sciences at Mercer 
iversity southern School of Pharmacy was the Collaborating Investigator on this 
ant. His help has proved to be invaluable in the critical pharmacological evalua- 
on of our test compounds. In the design of bioassay experiments, the interpreta-
on of biological results and the training of technicians and students in the work 
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rformed under this grant, he has proved to be a great asset to this effort. Also, 
Sheldon W. May, Professor of Biochemistry at Ga. Tech, who was a consultant on 
is project has contributed quite significantly to the planning and execution of 
ese experiments. He ,  is an expert in the oxygenation of olefinic substrates by a 
mber of enzymes, and it was in his laboratories that PAME was conceived and tested 
veral of his graduate students have worked on this project and have both learned 
td contributed to the work of this project. Our technician, Julie Lange, was first 
1 undergraduate researcher in Dr. May's group who, after graduation, worked full 
Jae on this project over the last year. Stephen Padgette and Jin Hee Han, both 
aduate students at Ga. Tech, have worked on this project and have had the oppor-
lnity to expand their biochemistry training to include pharmacology and bioassay 
rperimentation. 
IV. Publications Resulting 
A. Abstracts: 
Herman, H.R., Mueller, P.W., Padgette, S.R., Pollock,S.H., Phillips $ R.S 
AND May, S.W. (1982) Fed. Proc. Amer. Soc. Exptl. Biol. 41, 1588. 
Herman, H.H., Pollock, S.R., Han, J.H., Lange, J.R., and May, S.W. 
(1983) Fed. Proc. (in preparation). 
B. Presentations 
abstract above was presented at the national meeting of FASEB in New 
Orleans, La. in April, 1982 by Heath H. Berman. 
C. Manuscripts 
Herman, H.H., Pollock, S.R., Padgette, S.R., and may, S.W. (1982) 
phenyl 2-Aminoethyl sulfide: Effects on the Cardiovascular responses 
of the Anesthetized Dog. J. Cardiovas. Pharm. (submitted and protision-
ally accepted - MS #8293). 
Herman, H.H., Padgette, s.R., Mueller,P.W., Phillips, R.S., and May, 
S.W. (1982) Phenyl 1-Aminomethyl Ethene: A Novel Olefinic DBH Substra 
and Neuroteransmitter Analog. J. Biol. Chem. (in preparation). 
V. Research Continuation 
Unfortunately, the work of this project cannot continue at the pace of 
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e past year. Our inability to secure a Continuation from the Ga. Affiliate of 
e AHA at its May, 1982 meeting (when none of these results were apparent) has 
ant that we have had to let go our technician, Julie Lange. Also, because of the 
gh cost of the animals necessary for the indicated experimentation, we will have 
■ greatly reduce this aspect of our work. 
We will apply for another grant from the Ga. Affiliate of the American Heart 
;sociation in the coming weeks, however, although at best this will mean that 
mcentrated work will, begin again in the summer of 1983. A limited amount of 
Irk will continue on this project using the laboratories of Dr. S. W. May at 
i. Tech, under whom Dr. Herman will work as a researcher on an unrelated grant. 
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